TRPM2 and neuroblastoma: When TRPM2 is inhibited by a dominant splice variant13 or deleted using CRISPR technology19, neuroblastoma cell proliferation is reduced in vitro and in xenografts, and sensitivity to doxorubicin is significantly increased.